NPCE

SEC source: 0001209191-24-002942 · doc4.xml · nonDerivative · entry 1

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,208

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-24-002596 · doc4.xml · nonDerivative · entry 3

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,351

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.08, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

SEC source: 0001209191-24-002596 · doc4.xml · nonDerivative · entry 2

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,014

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.125, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · derivative · entry 35

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,449

Underlying: Common Stock · 40,000 shares

Expires 2030-11-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments commencing February 1, 2017.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · derivative · entry 34

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,234

Underlying: Common Stock · 12,234 shares

Expires 2030-11-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments commencing February 1, 2017.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · derivative · entry 33

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192

Underlying: Common Stock · 192 shares

Expires 2030-11-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on July 1, 2012; 1/48th of the shares subject to the option vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · derivative · entry 32

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 192 shares

Expires 2030-11-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on July 1, 2013; 1/48th of the shares subject to the option vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · derivative · entry 31

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 192 shares

Expires 2030-11-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on July 1, 2015; 1/48th of the shares subject to the option vest in 36 equal monthly installments thereafter.

F2 · derivative.underlying: 25% of the shares subject to the option vest on July 1, 2015; 1/48th of the shares subject to the option vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 30

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 29

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 28

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,246

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 27

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,054

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 26

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,862

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-24-002596 · doc4.xml · nonDerivative · entry 1

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,937

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.165, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-24-002322 · doc4.xml · nonDerivative · entry 2

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,199

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-24-002322 · doc4.xml · nonDerivative · entry 1

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.06, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 12

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,076

SEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 12

Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,116

SEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 3

Geiger Uri · CIK 0001467361 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,708

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 3

Fischer Frank M · CIK 0001297260 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 574,869

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018090 · form4-06242025_040605.xml · nonDerivative · entry 3

LACOB JOSEPH · CIK 0001215490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,136

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 3

Kumar Rakhi · CIK 0001856296 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,335

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001209191-23-059946 · doc4.xml · nonDerivative · entry 2

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,027

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.18, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-23-059946 · doc4.xml · nonDerivative · entry 1

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,327

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-23-059564 · doc4.xml · nonDerivative · entry 1

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,429

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.27, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-23-057715 · doc4.xml · nonDerivative · entry 1

Morrell Martha · CIK 0001855616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,159

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.05 to $8.265, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 11

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,340

SEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 11

Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,328

SEC source: 0001062993-23-021754 · form4.xml · nonDerivative · entry 3

KCK LTD. · CIK 0001657662 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,593,773

SEC source: 0001062993-23-021754 · form4.xml · nonDerivative · entry 2

KCK LTD. · CIK 0001657662 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,597,014

SEC source: 0001062993-23-021754 · form4.xml · nonDerivative · entry 1

KCK LTD. · CIK 0001657662 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,604,296

SEC source: 0000950170-23-066847 · ownership.xml · nonDerivative · entry 2

KCK LTD. · CIK 0001657662 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,609,940

SEC source: 0000950170-23-066847 · ownership.xml · nonDerivative · entry 1

KCK LTD. · CIK 0001657662 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,614,621

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 10

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,643

SEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 10

Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,338

SEC source: 0000947871-23-000978 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,003,967

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F2 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000978 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,004,667

F1 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F2 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 2

Geiger Uri · CIK 0001467361 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,557

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 2

Fischer Frank M · CIK 0001297260 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572,566

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018090 · form4-06242025_040605.xml · nonDerivative · entry 2

LACOB JOSEPH · CIK 0001215490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,045

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,881

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 9

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,874

SEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 9

Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,517

SEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 8

Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,176

SEC source: 0001415889-25-005559 · form4-02252025_100218.xml · nonDerivative · entry 8

Kuhn Rebecca · CIK 0001855659 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,527

SEC source: 0001209191-23-042748 · doc4.xml · derivative · entry 1

Becker Joel · CIK 0001533175 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 380,424

Underlying: Common Stock · 380,424 shares

Expires 2033-07-17

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on July 10, 2024; 1/48th of the shares subject to the option vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 1

Geiger Uri · CIK 0001467361 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,337

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 1

Fischer Frank M · CIK 0001297260 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 570,126

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018090 · form4-06242025_040605.xml · nonDerivative · entry 1

LACOB JOSEPH · CIK 0001215490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,889

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

SEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,340

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.